Esco Lifesciences $200 million Series A financing
We are advising Esco Lifesciences on its Series A financing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Charles River Laboratories acquisition of Vigene Biosciences
We are advising Charles River on the acquisition
Roivant Sciences combination with Montes Archimedes Acquisition
We are advising Roivant Sciences on its combination with a SPAC
Evernorth acquisition of MDLIVE
We are advising MDLIVE on the transaction
Reckitt Benckiser Group acquisition of Biofreeze
We are advising RB on the acquisition
Charles River Laboratories $875 million acquisition of Cognate
We advised Charles River on the acquisition of a cell and gene therapy contract development and manufacturing organization
Cornell Capital acquires trustaff and CardioSolution in combination with Stella
We are advising Cornell Capital on the acquisition
ImmunityBio merger with NantKwest
Davis Polk is advising Goldman Sachs & Co. LLC and Lazard Frères & Co. LLC as financial advisers to ImmunityBio, Inc. in connection with its 100% stock-for-stock merger with…
Signify Health acquisition of PatientBlox
Davis Polk advised Signify Health on its acquisition of PatientBlox. The acquisition accelerates Signify’s prospective provider payment capabilities for episodes of care, supporting the…
China Biologic going-private transaction
Davis Polk is advising the special committee of the board of directors of China Biologic Products Holdings, Inc. (“China Biologic”) in connection with the going-private acquisition of China…